换一批Validation and determination of taselisib, a β-sparing phosphoinositide 3-kinase (PI3K) inhibitor, in human plasma by LC-MS/MS.
第一作者：
X,Ding
第一单位：
Genentech, Drug Metabolism and Pharmacokinetics, 1 DNA Way, South San Francisco, CA 94080, United States. Electronic address: ding.xiao@gene.com.
作者：
医学主题词
抗肿瘤药(Antineoplastic Agents);曲线下面积(Area Under Curve);校准(Calibration);色谱法, 液相(Chromatography, Liquid);色谱法, 反相(Chromatography, Reverse-Phase);药物稳定性(Drug Stability);药物贮藏(Drug Storage);半衰期(Half-Life);人类(Humans);咪唑类(Imidazoles);线性模型(Linear Models);氧氮杂|艹卓|类(Oxazepines);结果可重复性(Reproducibility of Results);固相萃取(Solid Phase Extraction);串联质谱法(Tandem Mass Spectrometry);温度(Temperature);时间因素(Time Factors)
DOI
10.1016/j.jpba.2016.04.030
PMID
27187764
发布时间
2019-12-10
- 浏览26
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
